IHC & ISH
NeoTYPE™ Cancer Profiles
NeoGenomics Laboratories is a leader in precision diagnostics and is at the forefront of PD-L1/PD-1 immunotherapy testing. PD-L1 testing is an immunohistochemical assay that detects the level and expression sites of PD-L1 protein. As a companion/complementary diagnostic for certain tumors and indications, it helps identify patients for treatments including KEYTRUDA®1, OPDIVO®2, TECENTRIQ®3 and IMFINZI™4. Our broad offering, depth of pathology expertise and experience in immuno-oncology testing make us an ideal partner for your clinical or research testing needs.
PD-L1 IHC and PD-1 IHC can be ordered as stand-alone tests or in any combination with other IHC, FISH, or molecular tests offered. PD-L1 22C3 pharmDx IHC is also a standard component of solid tumor NeoTYPE™ Cancer Profiles, which offer multimethod analyses of broad or tumor-specific biomarker profiles.
Dr. Maher Albitar, NeoGenomics’ CMO and Director of R&D, delivered the talk “Comparison of PD-L1 Companion, Complementary and Laboratory Developed Tests with Molecular Profiling” at Immunotherapy World on January 18th, 2017.